58 |
Basic toxicokinetics |
Jul. 2023 |
4 tables, 1 exec summ |
TG417, TG 319A, TG319B |
59 |
Dermal absorption |
Jul. 2023 |
2 tables, 1 exec summ |
TG427, TG428 |
60 |
Acute toxicity: oral |
Jul. 2023 |
2 tables, 2 exec summ |
TG401, TG420, TG423, TG425 |
61 |
Acute toxicity: inhalation |
Jul. 2023 |
3 tables, 2 exec summ |
TG403, TG433, TG436 |
62 |
Acute toxicity: dermal |
Jul. 2023 |
2 tables, 1 exec summ |
TG402 |
63 |
Acute toxicity: other routes |
Jul. 2023 |
2 tables |
none |
64 |
Skin irritation/corrosion |
Jul. 2023 |
1 table, 2 exec summ |
TG404, TG430, TG431, TG435, TG439 |
65 |
Eye irritation |
Jul. 2023 |
1 table, 2 exec summ |
TG405, TG437, TG438, TG460, TG491, TG492, TG494 |
66-1 |
Skin sensitisation |
Jul. 2023 |
2 tables, 2 exec summ |
TG406, TG429, TG442A, TG442B, TG442C, TG442D, TG442E, TG497 |
66-2 |
Respiratory sensitisation |
Jul. 2023 |
none |
none |
66-3 |
In vitro phototoxicity |
Jul. 2023 |
2 tables |
TG432, TG495, TG498 |
67 |
Repeated dose toxicity: oral |
Jul. 2023 |
14 tables, 4 exec summ |
TG407, TG408, TG409, TG419, TG422, TG424, TG452, TG453 |
68 |
Repeated dose toxicity: inhalation |
Jul. 2023 |
11 tables, 3 exec summ |
TG412, TG413, TG422, TG452, TG453 |
69-1 |
Repeated dose toxicity: dermal |
Jul. 2023 |
12 tables, 3 exec summ |
TG410, TG411, TG422, TG452, TG453 |
69-2 |
Repeated dose toxicity: other routes |
Jul. 2023 |
none |
none |
70 |
Genetic toxicity in vitro |
Jul. 2023 |
7 tables, 4 exec summ |
TG471, TG472, TG473, TG476, TG479, TG480, TG481, TG482, TG487, TG490 |
71 |
Genetic toxicity in vivo |
Jul. 2023 |
4 tables, 1 exec summ |
TG474, TG475, TG477, TG478, TG483, TG484, TG485, TG486, TG488, TG489
|
72 |
Carcinogenicity |
Jul. 2023 |
11 tables, 3 exec summ |
TG451, TG453 |
73 |
Toxicity to reproduction |
Jul. 2023 |
12 tables, 1 exec summ |
TG415, TG416, TG421, TG422, TG426, TG443 |
74 |
Developmental toxicity/teratogenicity |
Jul. 2023 |
7 tables, 2 exec summ |
TG414 |
75-1 |
Toxicity to reproduction: other studies |
Jul. 2023 |
none |
none |
75-2 |
Endocrine disrupter screening - in vitro |
Jul. 2023 |
none |
TG455, TG456, TG458, TG493 |
75-3 |
Endocrine disruptor mammalian screening - In vivo (level 3) |
Jul. 2023 |
12 tables |
TG440, TG441 |
76 |
Neurotoxicity |
Jul. 2023 |
24 tables, 3 exec summ |
TG407, TG408, TG412, TG413, TG418, TG419, TG422, TG424, TG426
|
77 |
Immunotoxicity |
Jul. 2023 |
9 tables, 2 exec summ |
none |
78 |
Specific investigations: other studies |
Jul. 2023 |
none |
none |
79 |
Health surveillance data |
Jul. 2023 |
none |
none |
80 |
Epidemiological data |
Jul. 2023 |
1 table |
none |
81 |
Direct observations: clinical cases, poisoning incidents and other |
Jul. 2023 |
none |
none |
82 |
Sensitisation data (humans) |
Jul. 2023 |
none |
none |
83 |
Exposure-related observations in humans: other data |
Jul. 2023 |
none |
none |
84 |
Toxic effects on livestock and pets |
Jul. 2023 |
3 tables |
none |
86 |
Additional toxicological information |
Jul. 2023 |
none |
none |